Bayesian model of disease progression in GNE myopathy
Melanie Quintana(Berry & Associates (United States)), Nuria Carrillo(National Institutes of Health), Scott Berry(Queen's University), Mark Fitzgerald(Berry & Associates (United States)), Joseph A. Shrader(National Institutes of Health Clinical Center), William A. Gahl(National Institute of Child Health), Christina Slota(National Institutes of Health), Galen O. Joe(National Institutes of Health Clinical Center), John C. McKew(National Institutes of Health)
Cited by 25
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818